[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342315-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342315-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cost-effectiveness-of-serum-pepsinogen-as-a-gastric-cancer-targeted-screening-strategy-in-the-united-states","Cost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States","","Noninvasive serum pepsinogen (PG) screening is proposed to improve early detection and prevention of gastric cancer (GC), addressing the high cost and invasiveness of standard endoscopic screening. A patient-level state transition microsimulation compares one-time PG screening at age 40 versus no screening in an average-risk US cohort, evaluating life expectancy, quality-adjusted life years, total costs, incidence, and mortality. Base-case PG sensitivity and specificity were 34.1% and 94.7%. Results show favorable cost-effectiveness and meaningful reductions in lifetime GC incidence and cumulative GC mortality.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cost-effectiveness-of-serum-pepsinogen-as-a-gastric-cancer-targeted-screening-strategy-in-the-united-states/342315/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cost-effectiveness-of-serum-pepsinogen-as-a-gastric-cancer-targeted-screening-strategy-in-the-united-states/342315.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the study evaluate cost-effectiveness of PG screening for gastric cancer?","Question",{"text":63,"@type":64},"It uses a patient-level state transition microsimulation comparing one-time serum pepsinogen screening at age 40 with no screening, estimating life expectancy, quality-adjusted life years, total costs, and incremental cost-effectiveness ratios.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the base-case performance characteristics of the pepsinogen test?",{"text":68,"@type":64},"The base-case PG sensitivity and specificity were 34.1% and 94.7%, and additional performance ranges were examined in sensitivity analyses.",{"name":70,"@type":61,"acceptedAnswer":71},"What benefits did PG screening produce in the model?",{"text":72,"@type":64},"PG screening was cost-effective and led to a 10.9% relative reduction in lifetime GC incidence and a 10.8% relative decrease in cumulative GC mortality, with shifts toward more localized diagnoses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342315,1791035703,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Gastro Hep Advances 2025;4:100564  \nORIGINAL RESEARCH—CLINICAL   \nCost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States  \nAaron Oh, 1 Sheila D. Rustgi,2 Chin Hur,2 and Haejin In 1 ,3 ,4  \n1Albert Einstein College of Medicine, New York, New York; 2Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, New York; 3Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey; and 4Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey  \nBACKGROUND AND AIMS: Current gastric cancer (GC) screening modalities are invasive and expensive. Noninvasive screening for GC precursors with serum pepsinogen (PG) may improve early detection and prevention. Test characteristics of PG based on US prospective data was recently reported and used to study the cost-effectiveness of PG screening vs no screening in the US. METHODS: A patient-level state transition microsimulation of gastric adenocarcinoma analyzed noninvasive screening vs no screening in a hypothetical cohort of average risk US individuals. Primary outcomes included life expectancy, quality-adjusted life years, total costs, and incremental cost-effectiveness ratios. Secondary outcomes included total GC incidence and mortality. Base-case PG sensitivity and speciﬁcity were 34.1% and 94.7%, respectively, with a wide range of PG performance characteristics also examined. RESULTS: One-time serum PG screening at age 40 was costeffective compared to no screening with an incremental costeffectiveness ratio of $4913.29 per quality-adjusted life year. PG screening resulted in 10.9% relative reduction in lifetime GC incidence and 10 . 8% relative decrease in cumulative GC mortality. Localized stage at diagnosis increased from 30.5% to 33.6% and metastatic stage decreased from 40.8% to 37.4% . Sensitivity analysis showed PG screening was most sensitive to endoscopy costs, chronic atrophic gastritis quality of life, and PG prevalence. PG screening remained cost-effective across a wide range of test values. CONCLUSION: PG screening is a costeffective strategy to improve GC mortality; however, mortality beneﬁt will depend on the test characteristics of the biomarker. Future blood-based screening tests that have better performance characteristics could further improve GC prevention.  \nKeywords: Gastric Cancer; Serum Pepsinogen; Cancer Screening; Cancer Prevention; Cost-Effectiveness Analysis  \nIntroduction  \nGastric cancer (GC) remains  \nconcern, ranking fourth in  \na major global health cancer deaths world-  \nwide.1 Although incidence of GC is steadily decreasing in the United States (US), a low 5-year survival rate of 36% reﬂects the frequency with which it is diagnosed at late stage.2 GC disproportionately affects racial and ethnic minorities in the US. The American Association for Cancer Research State  \nof Cancer Health Disparities in 2022 report highlight that GC has the highest cancer-speciﬁc disparity in Hispanics, and second highest in Blacks and Asian/Paciﬁc Islanders with a doubling of risk for cancer speciﬁc death in these groups compared to Whites (rate ratio 1 .9–2. 0) .3  \nIn countries with high GC incidence, screening efforts have focused on early detection of gastric lesions where curative treatment is more effective in order to reduce mortality.4 Although esophagogastroduodenoscopy (EGD) is the gold standard for screening,5 its high cost and invasive nature hinder population-wide screening in countries with low GC incidence like the US.6 Targeted screening, which identiﬁes persons at higher risk of developing GC to undergo further evaluation, may reduce the burden of this disease in low incidence regions. Once precancerous lesions are identiﬁed, recent guidelines including American Gastroenterological Association, European Society of Gastrointestinal Endoscopy and British Society of Gastroenterology guidel","cbCaigTosYyqxI37","https://ap.wps.com/l/cbCaigTosYyqxI37","pdf",748163,"English","# Introduction\n## Background on gastric cancer burden and screening gaps\n## Targeted screening rationale and guideline context\n# Methods\n## Patient-level microsimulation and outcomes\n## PG test characteristics and scenario inputs\n# Results\n## Cost-effectiveness at age 40\n## Impact on incidence, mortality, and stage distribution\n## Sensitivity analyses\n# Conclusion\n## Dependence on biomarker performance and future directions","[{\"question\":\"How does the study evaluate cost-effectiveness of PG screening for gastric cancer?\",\"answer\":\"It uses a patient-level state transition microsimulation comparing one-time serum pepsinogen screening at age 40 with no screening, estimating life expectancy, quality-adjusted life years, total costs, and incremental cost-effectiveness ratios.\"},{\"question\":\"What were the base-case performance characteristics of the pepsinogen test?\",\"answer\":\"The base-case PG sensitivity and specificity were 34.1% and 94.7%, and additional performance ranges were examined in sensitivity analyses.\"},{\"question\":\"What benefits did PG screening produce in the model?\",\"answer\":\"PG screening was cost-effective and led to a 10.9% relative reduction in lifetime GC incidence and a 10.8% relative decrease in cumulative GC mortality, with shifts toward more localized diagnoses.\"}]","Cost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States | PDF",1790046096,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c1aef8c3fa4a3073f726a1ae75c243e.webp",983,1296,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9b6226035847bb2b2ed7acf5d4c9976.webp",982,1294,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f736df7a908d6d2950d07e247205abfc.webp",981,1293,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53d2316d463ba635e201283a06e7f5f8.webp",980,1292]